Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333354 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL18154527 | 0.80 | — | — | |
| SCHEMBL5839643 | 0.79 | — | — | |
| Urea SCHEMBL1100629 | 0.72 | PYGM (0.31) | — | |
| SCHEMBL13058104 | 0.71 | GAA (0.48) | GAAMEN1KMT2A | |
| SCHEMBL1646396 | 0.69 | — | — | |
| Morpholine SCHEMBL7787449 | 0.67 | MEN1 (0.50) | GAAMEN1KMT2AKDM4ECYP2C9 | |
| SCHEMBL896392 | 0.67 | — | — | |
| SCHEMBL9579603 | 0.67 | — | — | |
| Morpholine SCHEMBL4996263 | 0.66 | GAA (0.55) | GAAMEN1KMT2AKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603909-A4 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7135469-B2 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | BRISTOL MYERS SQUIBB, CO. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1603909-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | Brystol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040214808-A1 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-28 | — | — | US | disclosed |
| WO-2004083177-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214808-A1 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | TFPI, F12, F2 | GAA 1005/4885MEN1 766/4885KMT2A 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.